Abstract:Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of pathological cardiac hypertrophy can effectively reduce the occurrence of heart failure. Abundant factors, such as adrenergic, angiotensin, and endothelin (ET-1) receptors, have been shown to participate in the regulation of pathological cardiac hypertrophy. Recently, an increasing number of studies have indicated that circRNA and circRNA-miRNA–mRNA network regulation is indispensable for the posttranscriptional regulation of mRNA in cardiac hypertrophy. In our study, the morphological, cardiac function and pathological changes during cardiac hypertrophy were investigated. RNA sequencing identified 93 circRNAs that were differentially expressed in the TAC_2w group, and 55 circRNAs in the TAC_4w group compared with the sham group. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses identified several significant pathways, including hypertrophic cardiomyopathy, extracellular matrix (ECM)-receptor interaction and focal adhesion. Coexpression analyses were performed for differentially expressed circRNAs and differentially expressed mRNAs. Based on gene set enrichment analysis (GSEA), 8 circRNAs (mmu-Nfkb1_0001, mmu-Smad4_0007, mmu-Hecw2_0009, mmu-Itgbl1_0002, mmu-Lrrc2_0005, mmu-Cpeb3_0007, mmu-Ryr2_0040, and mmu-Rtn4_0001) involved in cardiac hypertrophy and cardiac fibrosis were identified. We validated some key circRNAs by qPCR. The crucial coexpression of circRNA–mRNA and its interaction with miRNA showed the possible mechanism of circRNAs in the process of cardiac dysfunction. Our results may provide promising targets for the treatment of pathological cardiac hypertrophy and fibrosis.

Molecular Biomarkers in Cardiac Hypertrophy

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Biomarkers for heart failure: small molecules with high clinical relevance

MicroRNAs target gene and signaling pathway by bioinformatics analysis in the cardiac hypertrophy.

LncRNAs in Cardiac Hypertrophy: from Basic Science to Clinical Application

Signaling Pathways in Cardiac Hypertrophy

The Biomarkers for Acute Myocardial Infarction and Heart Failure.

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

The role and molecular mechanism of epigenetics in cardiac hypertrophy

Mitochondrial function in cardiac hypertrophy.

Mitochondria-associated endoplasmic reticulum membranes and cardiac hypertrophy: Molecular mechanisms and therapeutic targets

MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy.

Mechanisms of physiological and pathological cardiac hypertrophy

mir15a/mir16‐1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

Role of microRNAs in cardiac hypertrophy and heart failure.

Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy

The Mechanism of Myocardial Hypertrophy Regulated by the Interaction Between Mhrt and Myocardin.

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis

A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure